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Background. The purpose of this study was to examine the
lipid abnormalities associated with urinary albumin excretion
rate (UAER) in type 2 diabetic patients.
Methods. A total of 275 (122 men and 153 women; aged 60.6 ±
11.1 years) patients were selected with stringent criteria to pre-
vent confounders. Normoalbuminuria (N = 152) and albumin-
uria (N = 123) were defined as urinary albumin-to-creatinine
ratio (ACR) of <30 and ≥30 lg/mg, respectively. Total choles-
terol, triglycerides, low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol, and apolipoproteins A1
(ApoA1) and B (ApoB) were measured and non-HDL choles-
terol calculated. The subjects were divided into four phenotypes
based on triglycerides (<1.5 or ≥1.5 mmol/L) and ApoB (<1.2
or ≥1.2 g/L).
Results. Total cholesterol, ApoB, and non-HDL cholesterol
were significantly (P <0.05) higher in patients with albuminuria.
For quartiles of the lipid parameters, prevalences of albumin-
uria showed significant association with ApoB and non-HDL
cholesterol (P trend <0.05). After adjusting for age, systolic
blood pressure and hemoglobin A1c (HbA1c) correlation co-
efficients between the natural logarithm (ln) ACR and lipid
parameters, odds ratios for albuminuria, and standardized re-
gression coefficients for ln ACR, were significant for total
cholesterol, ApoB and non-HDL cholesterol in all subjects and
in men, but only ApoB was significant in women. For patients
with normoalbuminuria, frequencies of normotriglycerides/
normo-ApoB, hypertriglycerides/normo-ApoB, normotriglyc-
erides/hyper-ApoB, and hypertriglycerides/hyper-ApoB were
44.7%, 28.9%, 10.5%, and 15.8%, respectively; and were 30.1%,
19.5%, 15.4%, and 35.0% for patients with albuminuria (P <
0.001). The respective adjusted odds ratio for albuminuria for
the four phenotypes was 1.00, 1.04 (0.54 to 2.00), 2.25 (1.02 to
5.00), and 3.38 (1.75 to 6.53).
Conclusion. Increased UAER is associated with ApoB-
containing lipoproteins and the phenotype of hypertriglyc-
erides/hyper-ApoB is associated with the highest risk of
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albuminuria. The surrogate marker of non-HDL cholesterol for
ApoB is more applicable to the diabetic men.
Increased urinary albumin excretion rate (UAER),
even in the early microalbuminuric range, is associated
with progressive renal failure and increased cardiovascu-
lar morbidity and mortality in diabetic and nondiabetic
patients [1–8]. The mechanisms linking increased UAER
and increased risk of cardiovascular disease remain to
be answered, but one of the mechanisms is its link with
atherogenic lipoproteins. Although lipid metabolism has
been extensively investigated in diabetes, little informa-
tion is available concerning the lipid abnormalities as-
sociated with increased UAER, especially in the early
stage without impairment in renal function. In a prospec-
tive study from the Steno Diabetes Center, the baseline
total cholesterol but not high-density lipoprotein (HDL)
cholesterol was an independent risk factor for microalbu-
minuria and overt diabetic nephropathy in type 2 diabetic
patients [9]. However, apolipoprotein (Apo) levels were
not measured in that study. Samuelsson et al reported that
ApoB was associated with a declining glomerular filtra-
tion rate (GFR) [10], and that renal dyslipidemia was pre-
dominantly associated with the accumulation of ApoB-
containing lipoproteins in both sclerotic and nonsclerotic
glomeruli [11]. However, these studies evaluated patients
with more advanced renal disease and not specifically in
diabetic patients. A Japanese study showed that type 2
diabetic patients who progressed from normoalbumin-
uria to microalbuminuria after 2 years had significantly
higher baseline triglycerides and ApoB levels [12]. How-
ever, this study did not evaluate the interaction between
triglycerides and ApoB.
Assessments of the conventional lipid profile includ-
ing total cholesterol, triglycerides, HDL cholesterol and
low-density lipoprotein (LDL) cholesterol do not always
appropriately reflect the atherogenicity associated with
dyslipidemia in the diabetic patients. Instead, measure-
ment of plasma ApoB may reflect the total number of
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atherogenic lipoprotein particles, including very low-
density lipoprotein (VLDL), LDL, intermediate-density
lipoprotein (IDL), and lipoprotein(a) [13]. Because
ApoB is not always measured in clinical practice, the
National Cholesterol Education Program-Adult Treat-
ment Panel III (NCEP-ATP III) recommended the cal-
culation of non-HDL cholesterol as a surrogate marker
[14]. However, Sniderman, Scantlebury, and Cianflone
[15] suggested that lipid measurement should include
ApoB (rather than the surrogate non-HDL cholesterol)
and patients should be classified based on triglyceride and
ApoB levels because hypertriglyceride/hyper-ApoB phe-
notype is more atherogenic and is characterized by high
triglyceride, low HDL cholesterol and increased numbers
of small, dense LDL particles [15]. To the best of our
knowledge, whether this phenotype is associated with in-
creased UAER in type 2 diabetic patients has not been
examined. Therefore, the objective of this study was to
evaluate the relationship between UAER and the mea-
sured lipid profile, including total cholesterol, triglyc-
erides, HDL cholesterol, LDL cholesterol, ApoA1, and
ApoB, the calculated non-HDL cholesterol, and the phe-




The study was approved by the Department of Health,
Executive Yuan, Republic of China with subjects partic-
ipating voluntary with their informed consent. In a dia-
betic clinic at the National Taiwan University Hospital,
the demographic data and basic information of the pa-
tients have been collected for convenience of follow-up,
when they attended the clinic for the first time. Among
them, there were 777 diabetic patients (339 men and 438
women) aged 30 years or older with the diagnosis of
type 2 diabetes mellitus. The patients were treated with
either oral antidiabetic drugs or insulin at the time of
recruitment. They did not show a history of diabetic ke-
toacidosis at the onset of diabetes mellitus, nor did they
receive insulin treatment within 1 year of diagnosis. All
of these patients were invited to participate in a health
examination and a total of 610 patients (268 men and 342
women) (78.5%) actually participated. The distribution
of age and gender between those who did not partici-
pate and those who participated were not different signif-
icantly. For those who did not participate and those who
participated, the respective age was 62.0 ± 10.6 years and
63.3±10.8 years, respectively; and the respective percent-
age of men was 42.5% and 43.9%. In order to evaluate
the lipid abnormalities associated with UAER without
the influence of potential confounders, the subjects re-
cruited into the present study were selected from the 610
subjects based on the following stringent criteria: (1) non-
smoker and nonconsumer of alcoholic beverages; (2) no
history of hypertension and not taking any antihyperten-
sive agent; (3) no history or symptoms of congestive heart
failure and not receiving treatment for such; (4) no use of
lipid-lowering agents, antibiotics, hormone replacements,
or vitamin supplements; (5) normal renal function [blood
urea nitrogen (BUN) ≤8.6 mmol/L (24 mg/dL) and serum
creatinine ≤106.1 lmol/L (1.2 mg/dL)]; and (6) no acute
illness or fever. As a result, a total of 275 patients (122 men
and 153 women) aged 60.6 ± 11.1 years were recruited.
Measurements of albumin-to-creatinine (ACR) and
calculation of creatinine clearance
The subjects were advised not to participate in vig-
orous physical activity one day before the examination.
Urinary specimen and blood samples were collected in
the early morning after the subjects fasted for at least
12 hours. First-void and midstream urine was collected;
this was followed by venous blood sampling. The concen-
tration of urine albumin was quantitatively measured by
means of particle-enhanced turbidimetric immunoassay
(Biolatex, Logrono, Spain). The urine creatinine concen-
tration was measured after 10× dilution on an automatic
biochemistry analyzer (Cobas Mira S) (Roche Diagnos-
tica, Basel, Switzerland) with reagents obtained from
Randox Laboratories Ltd. (Antrium, UK). ACR was cal-
culated by dividing the urinary albumin concentration in
micrograms by the urinary creatinine concentration in
milligrams. An ACR ≥30 lg/mg was defined as albumin-
uria, and <30 lg/mg as normoalbuminuria. Creatinine
clearance (mL/min) was calculated from the Cockcroft-
Gault formulae as: [(140 − age in years) ∗ body weight
in kg]/(72 ∗ serum creatinine in mg/dL) [16]. For women,
the calculated values were multiplied by 0.85 [16].
Measurements of lipid parameters
Serum samples were used to determine total choles-
terol, triglycerides, HDL cholesterol, and LDL choles-
terol levels on an automatic biochemistry analyzer
(Cobas Mira S) (Roche Diagnostica) with reagents ob-
tained from Randox Laboratories Ltd. Serum ApoA1
and ApoB were measured with reagents obtained from
Raichem SPIA (Reagents Applications Inc., San Diego,
CA, USA). A tenfold dilution was made before assay
if the serum sample was turbid or triglyceride level was
>4.48 mmol/L (400 mg/dL).
Non-HDL cholesterol was calculated as total choles-
terol minus HDL cholesterol. The subjects were divided
into four phenotypes based on the levels of triglyc-
eride (<1.5 or ≥1.5 mmol/L) and ApoB (<1.2 or ≥1.2
g/L) as normotriglyceride/normo-ApoB, hypertriglyc-
eride/normo-ApoB, normotriglyceride/hyper-ApoB, and
hypertriglyceride/hyper-ApoB. The cutoffs followed
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those used by Sniderman et al [17] in a previous study.
The triglyceride cutoff was chosen because small dense
LDL particles become common above this value [18]. The
ApoB cutoff was applied because this level was used in
the Framingham Study [19] and the Quebec Cardiovas-
cular Study [20] for risk classification. Both of these two
cutoffs are also close to the 75th percentiles of triglyc-
eride and ApoB in the general population of Taiwan in a
community study [21].
Measurements of potential confounders
Age, gender, body mass index, diabetic duration,
systolic blood pressure, diastolic blood pressure, and
hemoglobin A1c (HbA1c) were treated as potential con-
founders.
Blood pressure was measured on the right arm after 20
minutes rest on a sitting position with a standard mer-
cury sphygmomanometer by the auscultatory method
between 8:00 a.m. and 10:00 a.m. The first perception
of successive sounds (Korotkoff phase I) was taken as
systolic blood pressure and the complete disappearance
of sound (Korotkoff phase V) was taken as diastolic
blood pressure. Body height in centimeters (cm) and body
weight in kilograms (kg) were measured with light clothes
and bare feet. Body mass index was calculated as body
weight in kg divided by the square of body height in me-
ters. HbA1c was measured by means of boronate affinity
chromatography with reagents obtained from the Primus
Corporation (Primus CLC385, Kansas City, MO, USA).
Statistical analyses
Because the distribution of ACR was highly skewed,
the natural logarithm of ACR (ln ACR) was used for sta-
tistical analyses. Continuous variables were expressed as
the mean± standard deviation (SD), and categorical vari-
ables, as percentages. P < 0.05 was considered to indicate
a statistically significant difference.
The measured lipid parameters (i.e., total choles-
terol, triglycerides, HDL cholesterol, LDL cholesterol,
ApoA1, and ApoB) and the calculated non-HDL choles-
terol were divided into quartiles and the prevalences of al-
buminuria among the quartiles of these parameters were
tested by linear test for trend.
Differences in the baseline characteristics between the
normoalbuminuric and albuminuric groups were tested
by using either the v 2 test or the Student t test. Corre-
lation coefficients between ln ACR and the continuous
potential confounders were generated. Age and the vari-
ables found to be associated with ln ACR or albuminuria
in the above analyses with P values <0.1 were adjusted in
further analyses of the correlation coefficients between ln
ACR and the lipid parameters and in the multiple logis-
tic regression and linear regression models, performed in
separate genders.
The lipid parameters and ln ACR among the four phe-
notypes were compared by one-way analysis of variance
(ANOVA) followed by multiple comparison test using
least significant difference (LSD). The frequencies of the
four phenotypes in patients with normoalbuminuria and
albuminuria were tested by chi-square test. The preva-
lences of albuminuria in the four phenotypes in all pa-
tients and in either gender were tested by linear test
for trend. Adjusted odds ratios for albuminuria in the
four phenotypes using the normotriglycerides/normo-
ApoB group as reference were estimated through logistic
regression.
RESULTS
Among the 275 patients, 152 had normoalbuminuria
and the other 123 had albuminuria. Comparisons of the
baseline characteristics between the normoalbuminuric
and albuminuric groups are shown in Table 1. The albu-
minuric group was characterized by significantly higher
levels of systolic blood pressure, total cholesterol, ApoB,
and non-HDL cholesterol. For the prevalences of albu-
minuria among the four quartiles of lipid parameters, only
ApoB and non-HDL cholesterol showed significant lin-
ear test for trend and they are illustrated in Figure 1.
In the correlation coefficient analyses between ln ACR
and the continuous potential confounders, ln ACR was
correlated with systolic blood pressure (c = 0.124, P <
0.05) and HbA1c (c = 0.100, P < 0.10) with P values
<0.10, and the P values for all of the other correlation
coefficients were>0.10. In the following analyses evaluat-
ing the association between UAER and lipid parameters,
age, systolic blood pressure, and HbA1c were adjusted.
In the correlation coefficient analyses between ln ACR
and the lipid parameters after adjusting for age, systolic
blood pressure, and HbA1c, ln ACR was correlated sig-
nificantly with total cholesterol, ApoB, and non-HDL
cholesterol in all subjects (c = 0.1422, 0.1949, and 0.1580,
respectively) and in the diabetic men (c = 0.1948, 0.2096,
and 0.2050, respectively), but only ApoB showed signifi-
cant correlation with ln ACR in the diabetic women (c =
0.1779).
Table 2 shows the odds ratios for albuminuria for the
lipid parameters after adjusting for age, systolic blood
pressure, and HbA1c. Total cholesterol, ApoB, and non-
HDL cholesterol showed significant adjusted odds ratios
for all subjects and for the diabetic men. For the diabetic
women, only ApoB showed significant odds ratio.
Table 3 shows the standardized regression coefficients
for ln ACR estimated by the lipid parameters after ad-
justing for age, systolic blood pressure, and HbA1c. The
standardized regression coefficients for total cholesterol,
ApoB, and non-HDL cholesterol were significant for all
subjects and for men, but only ApoB was significant for
women.
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Table 1. Baseline characteristics
Characteristics Total Normoalbuminuria Albuminuria
Number 275 152 123
Age years 60.6 ± 11.1 59.9 ± 10.3 61.5 ± 12.0
Gender (% men) 44.4 46.1 42.3
Body mass index kg/m2 24.5 ± 3.3 24.4 ± 3.3 24.6 ± 3.2
Diabetic duration years 11.0 ± 7.3 10.7 ± 7.0 11.4 ± 7.7
Systolic blood pressure mm Hg 127.8 ± 14.2 125.9 ± 14.9 130.2 ± 12.9a
Diastolic blood pressure mm Hg 76.2 ± 8.9 75.7 ± 8.4 76.8 ± 9.5
HbA1c% 7.7 ± 1.7 7.6 ± 1.7 7.9 ± 1.8
Total cholesterol mmol/L 5.25 ± 1.02 5.11 ± 1.00 5.42 ± 1.03a
Triglycerides mmol/L 1.79 ± 1.16 1.70 ± 1.07 1.90 ± 1.26
HDL cholesterol mmol/L 1.29 ± 0.39 1.33 ± 0.41 1.26 ± 0.36
LDL-cholesterol mmol/L 2.93 ± 0.77 2.87 ± 0.76 3.00 ± 0.77
ApoA1 g/L 1.43 ± 0.33 1.42 ± 0.33 1.44 ± 0.34
ApoB g/L 1.14 ± 0.34 1.06 ± 0.29 1.23 ± 0.37b
Non-HDL cholesterol mmol/L 3.95 ± 0.98 3.78 ± 0.96 4.16 ± 0.98b
Calculated creatinine clearance mL/min 71.5 ± 25.8 71.6 ± 21.1 71.2 ± 30.7
Abbreviations are: HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.
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Fig. 1. Prevalences of albuminuria by quartiles of apolipoprotein B
(ApoB) and non-high-density lipoprotein cholesterol (HDL-c).
Table 4 shows the levels of lipid parameters and ln
ACR by the four phenotypes and the frequency distribu-
tion and adjusted odds ratios for albuminuria by the four
phenotypes. In patients with normoalbuminuria and al-
buminuria, respectively, 26.3% and 50.4% of the patients
had hyper-ApoB disregard the level of triglycerides. All
of the lipid parameters differed significantly among the
four phenotypes and ln ACR increased accordingly.
DISCUSSION
The main findings of this study suggested that, among
the lipid parameters, only ApoB had the closest associa-
tion with increased UAER in both the diabetic men and
the diabetic women (Tables 2 to 4). Prevalences of albu-
minuria increased significantly with increasing quartiles
of ApoB (Fig. 1) and the association between ApoB and
increased UAER was consistently shown in the multiple
regression models, either when UAER was expressed as
a categorical variable of albuminuria in the logistic re-
gression model (Table 2) or as a continuous variable of
ln ACR in multiple linear regression (Table 3). Although
quartiles of non-HDL cholesterol also showed significant
test for trend for its association with the prevalences of al-
buminuria, the association was not as remarkable as with
ApoB (Fig. 1). Total cholesterol and non-HDL choles-
terol were also significantly associated with albuminuria
(Table 2) or ln ACR (Table 3), but the odds ratio for ApoB
was substantially higher than for non-HDL cholesterol
or total cholesterol (Table 2); and the degree of associ-
ation as expressed by the standardized regression coef-
ficient was also highest for ApoB (Table 3). This finding
conformed to a Japanese study showing that type 2 di-
abetic patients who progressed from normoalbuminuria
to microalbuminuria after 2 years had significantly higher
baseline ApoB [12]. Conventional practice is to quanti-
tate lipoproteins by their lipid moieties and LDL choles-
terol has always been regarded as the cornerstone of
disease association and treatment guideline [14]. How-
ever, LDL cholesterol was not found to be a good indica-
tor for albuminuria in this study (Tables 1 to 3). It should
be pointed out that measurement of LDL cholesterol con-
centration per se has neglected the impact of other highly
atherogenic particles such as VLDL, IDL, and lipopro-
tein(a) [13]. It is the number of all atherogenic lipoprotein
particles and not only the concentration of cholesterol in
the LDL particles that contribute to the development
of atherosclerosis. Therefore, LDL cholesterol is not as
good an indicator for the whole number of atherogenic
particles as ApoB is [13]. Although the NCEP-ATP III
recommended the calculation of non-HDL cholesterol as
a surrogate marker for ApoB [14], it is evident that total
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Table 2. Odds ratios for albuminuria after adjusting for age, systolic blood pressure, and hemoglobin A1c
Lipid parameters Total (N = 275) Men (N = 122) Women (N = 153)
Total cholesterol 1.334 (1.041–1.709)a 1.525 (1.008–2.307)a 1.214 (0.885–1.666)
Triglycerides 1.181 (0.950–1.469) 1.057 (0.726–1.539) 1.236 (0.932–1.639)
HDL cholesterol 0.618 (0.325–1.175) 0.749 (0.278–2.015) 0.519 (0.213–1.269)
LDL cholesterol 1.219 (0.885–1.680) 1.403 (0.845–2.329) 1.119 (0.733–1.708)
ApoA1 1.189 (0.569–2.486) 1.267 (0.427–3.753) 1.071 (0.379–3.023)
ApoB 4.517 (2.052–9.946)b 5.998 (1.619–22.219)b 3.836 (1.416–10.394)b
Non-HDL cholesterol 1.490 (1.143–1.942)b 1.610 (1.061–2.444)a 1.382 (0.977–1.956)
Abbreviations are: HDL, high-density lipoprotein; LDL, low-density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.
aP < 0.05; bP < 0.01.
Table 3. Standardized regression coefficients for natural logarithm of
albumin-to-creatinine ratio after adjusting for age, systolic blood
pressure, and hemoglobin A1c
Total Men Women
Lipid parameters (N = 275) (N = 122) (N = 153)
Total cholesterol 0.141a 0.195a 0.088
Triglycerides 0.094 0.050 0.103
HDL cholesterol −0.024 −0.023 −0.037
LDL cholesterol 0.093 0.114 0.072
ApoA1 0.101 0.088 0.084
ApoB 0.194b 0.214a 0.174a
Non-HDL cholesterol 0.157b 0.207a 0.109
Abbreviations are: HDL, high-density lipoprotein; LDL, low-density
lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.
aP < 0.05; bP < 0.01.
cholesterol or this surrogate marker was associated with
albuminuria or ln ACR only in the diabetic men but not
in the diabetic women (Tables 2 and 3). The cause for
this sexual discrepancy is unknown, but the results sug-
gested a need for the measurement of ApoB rather than
total cholesterol or the surrogate marker of non-HDL
cholesterol.
The positive association between triglycerides and the
progression to microalbuminuria in the Japanese study
[12] was not similarly observed in the present study. Nei-
ther triglyceride was associated with progression of hu-
man chronic renal insufficiency in the study by Samuels-
son et al [11]. However, the results supported that the
phenotype classification based on triglycerides and ApoB
could better identify the patients’ risk of albuminuria
(Table 4). Among the four phenotypes, hypertriglyc-
erides/hyper-ApoB was associated with the highest
risk, patients with normotriglycerides/hyper-ApoB had
an intermediate risk, and the risk in patients hav-
ing normo-ApoB is the lowest, disregard the level
of triglycerides (Table 4). Although the underlying
pathophysiologic mechanisms are not fully known, the
results are compatible with previous reports show-
ing intact or partially metabolized triglyceride-rich but
not cholesterol-rich ApoB-containing lipoproteins of
VLDL, IDL, and LDL fractions being more closely
associated with rapid loss of renal function [22, 23].
In patients with normotriglycerides, if ApoB was
not measured, the patients at high risk of albu-
minuria associated with normotriglycerides/hyper-ApoB
would not be identified (Table 4). A measurement of
ApoB in patients with hypertriglycerides could also
provide more information about their risk of albu-
minuria, because the adjusted odds ratio associated
with hypertriglycerides/hyper-ApoB phenotype was still
higher than that of the hypertriglycerides/normo-ApoB
phenotype (Table 4). Although not statistically signif-
icant (probably due to the small case number in the
group of normotriglycerides/hyper-ApoB), the trend
showed that in patients with hyper-ApoB, a simultaneous
increase in triglycerides (the hypertriglycerides/hyper-
ApoB phenotype) might suggest a higher risk of al-
buminuria than those with normotriglycerides (the
normotriglycerides/hyper-ApoB phenotype) (Table 4).
The cause/effect relationship between the lipid ab-
normalities and increased UAER cannot be easily dis-
cerned in this study. It is well known that dyslipidemia
can be resulted from renal disease, because dysregu-
lation of lipid metabolism and dyslipidemia can well
be demonstrated in animals following induction of pro-
teinuria with renal insufficiency [24–26]. Although the
underlying pathophysiologic mechanisms have not yet
been fully elucidated, increased hepatic synthesis and
decreased catabolism of lipoproteins and their delayed
removal from plasma have been documented in both an-
imals and humans [27–33]. However, what was investi-
gated in this study was not advanced renal disease, it was
the early stage of albuminuria that was investigated be-
cause all patients with abnormal renal function had been
excluded from the study. The study of Kashiwazaki et al
[35] suggested that the widespread endothelial damage
in type 2 diabetic patients with microalbuminuria might
lead to decreased release of lipoprotein lipase (LPL) moi-
ety bound to the endothelium resulting in an impaired
catabolism of triglyceride-rich lipoproteins. Although de-
creased LPL activity will slow down triglyceride clear-
ance leading to hypertriglycerides, it can not lead to an
elevated ApoB if LDL clearance is not markedly reduced
or in combination with a markedly enhanced VLDL
production. Whether early renal problem in the stage
of increased UAER as investigated in the present study
could cause increased secretion of VLDL particle from
the liver is not known, but in doubt.
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Table 4. Comparisons among the four phenotypes classified by triglycerides and apolipoprotein B
A B C D
Normotriglycerides/ Hypertriglycerides/ Normotriglycerides/ Hypertriglycerides/
normo-ApoB normo-ApoB hyper-ApoB hyper-ApoB P valueg
Number% P (chi-square test)
Total 105 (38.2%) 68 (24.7%) 35 (12.7%) 67 (24.4%) <0.001
Normoalbuminuria 68 (44.7%) 44 (28.9%) 16 (10.5%) 24 (15.8%)
Albuminuria 37 (30.1%) 24 (19.5%) 19 (15.4%) 43 (35.0%)
Total cholesterol mmol/L 4.82 ± 0.93 4.94 ± 0.83 5.78 ± 0.87 5.94 ± 0.94 <0.001b,c,d,e
Triglycerides mmol/L 0.96 ± 0.30 2.45 ± 0.93 1.04 ± 0.29 2.81 ± 1.27 <0.001a,c,d,e,f
HDL cholesterol mmol/L 1.44 ± 0.41 1.14 ± 0.36 1.32 ± 0.31 1.20 ± 0.34 <0.001a,c,d
LDL cholesterol mmol/L 2.73 ± 0.71 2.63 ± 0.63 3.41 ± 0.67 3.28 ± 0.78 <0.001b,c,d,e
ApoA1 g/L 1.40 ± 0.33 1.31 ± 0.35 1.53 ± 0.33 1.54 ± 0.28 <0.001b,c,d,e
ApoB g/L 0.92 ± 0.17 0.95 ± 0.15 1.47 ± 0.23 1.50 ± 0.27 <0.001b,c,d,e
Non-HDL cholesterol mmol/L 3.38 ± 0.82 3.80 ± 0.74 4.46 ± 0.77 4.74 ± 0.90 <0.001a,b,c,d,e
Ln ACR 3.14 ± 1.16 3.17 ± 1.12 3.64 ± 1.31 3.88 ± 1.24 <0.001b,c,e
Albuminuria% P (trend test)
Total 35.2 35.3 54.3 64.2 <0.001
Men 31.1 34.3 53.3 66.7 0.002
Women 38.2 36.4 55.0 62.5 0.01
Adjusted odds ratioh
Total 1.00 1.04 (0.54–2.00) 2.25 (1.02–5.00) 3.38 (1.75–6.53)
Men 1.00 1.15 (0.44–3.01) 2.73 (0.80–9.31) 4.26 (1.46–12.40)
Women 1.00 0.96 (0.39–2.37) 2.02 (0.70–5.84) 2.77 (1.18–6.46)
Abbreviations are: Normotriglycerides, triglycerides <1.5 mmol/l; hypertrigylcerides, triglycerides ≥1.5 mmol/L; normo-apolipoprotein B (ApoB), ApoB <1.2 g/L;
hyper-ApoB, ApoB ≥1.2 g/L; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ApoA1, apolipoprotein A1.
Multiple comparison test with least significant difference are significant for aA vs. B; bA vs. C; cA vs. D; dB vs. C; eB vs. D; fC vs. D.
gP by one-way analysis of variance unless otherwise specified.
hOdds ratios for albuminuria were adjusted for age, systolic blood pressure, and HbA1c.
On the other hand, elevated serum lipid concentration
may cause impairment and progression in renal func-
tion. For example, ApoB was associated with a declin-
ing GFR in an early study [10]. The same group later
reported that renal dyslipidemia was predominantly
associated with the accumulation of ApoB-containing
lipoproteins in both sclerotic and nonsclerotic glomeruli
[11]. Glomerular cells possess LDL receptors, and mesan-
gial and glomerular epithelial cells can internalize IDL
by means of both receptor- and nonreceptor-mediated
mechanisms [11]. A series of lipoprotein-induced cellu-
lar events occur in the glomeruli, similar to the vascular
effects of atherosclerosis [34]. The infiltration of athero-
genic lipoproteins into the glomerular endothelium and
mesangial cells can initiate a cascade of events, including
adhesion molecule expression, monocyte chemoattrac-
tant production, and release of reactive oxygen species,
that lead to early glomerular injury [34]. Therefore, al-
though dyslipidemia and renal dysfunction may perpetu-
ate each other, leading to accelerated atherosclerosis and
renal insufficiency, dyslipidemia leading to renal dysfunc-
tion seems to be much more likely in the early stage with
the more profound evidence from the prospective follow-
up studies [10–12] and the biologic plausibility [34]. How-
ever, much more investigations are required to settle this
controversial issue of cause and effect.
One strength of this study is the exclusion of many of
the potential confounders at the stage of patient recruit-
ment, making the two groups of patients with and without
albuminuria more comparable. Residual confounding ef-
fects were further considered and adjusted during the
stage of statistical analyses. The findings also suggested
that the lipid abnormalities associated with increased
UAER could not be ascribed to a change in the GFR,
because the normoalbuminuric and albuminuric groups
had comparable calculated creatinine clearance (Table 1)
and ln ACR was not correlated significantly with the cal-
culated creatinine clearance (data not shown). In further
analyses, even when calculated creatinine clearance was
additionally adjusted for, the results were similar (data
not shown). The lack of an association between ln ACR
and calculated creatinine clearance was not surprising,
because patients with elevated creatinine levels had al-
ready been excluded from the study at recruitment.
However, the cross-sectional design of this study was
not sufficient to confirm a causal relationship between the
lipid abnormalities and albuminuria or elevated UAER.
Since the patient cohort of the diabetic clinic recruited
in this study might not necessarily be representative for
patients not attending the diabetic clinic of this hospital,
selection bias remains possible. Therefore, the extension
of the results of this study to type 2 diabetic patients in
general remains to be confirmed. The cutoffs used to de-
fine the phenotypes are somewhat arbitrary, but this is
always the case. These cutoffs have been applied previ-
ously by other investigators [17] and are the values used
by the Quebec Cardiovascular Study [20] and the Fram-
ingham Study [19] to define increased risk. These values
are also close to the 75th percentiles of our population
[21]. Therefore, the use of these cutoff values avoided the
possible bias associated with the use of other self-selected
criteria and was surely much more reasonable.
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CONCLUSION
Among the lipid parameters of total cholesterol,
triglycerides, HDL cholesterol, LDL cholesterol,
ApoA1, ApoB, and non-HDL cholesterol, only ApoB
is significantly associated with albuminuria or ln ACR
in both genders. The use of non-HDL cholesterol as
a surrogate marker for ApoB might not be applicable
in the diabetic women. Patients with the phenotype of
hypertriglycerides/hyper-ApoB have the highest risk of
albuminuria.
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